Company intelligence / Profile preview

Enancio

Cesson-Sévigné, Brittany, France

Ownership: Private
Development stage: Other

Overview

Enancio was a French genomics software company focused on lossless compression and decompression of next-generation sequencing data. Its technology was designed to reduce genomic data storage and transfer costs while preserving data integrity, and it complemented sequencing informatics workflows rather than developing therapeutics. In July 2020, Illumina acquired Enancio's compression software and integrated the technology into its DRAGEN and cloud storage offerings. Enancio therefore should be viewed as a healthcare/bioinformatics infrastructure company, not a drug developer, with no disclosed therapeutic pipeline.

Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Illumina

Beyond the preview

Go deeper on Enancio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enancio.

Explore the full profile